Nebulised hypertonic saline in moderate-to-severe bronchiolitis: a randomised clinical trial.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: Final published version
License: All rights reserved
Serval ID
serval:BIB_2C97BE19B72F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Nebulised hypertonic saline in moderate-to-severe bronchiolitis: a randomised clinical trial.
Journal
Archives of disease in childhood
Author(s)
Jaquet-Pilloud R., Verga M.E., Russo M., Gehri M., Pauchard J.Y.
ISSN
1468-2044 (Electronic)
ISSN-L
0003-9888
Publication state
Published
Issued date
03/2020
Peer-reviewed
Oui
Volume
105
Number
3
Pages
236-240
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial
Publication Status: ppublish
Abstract
To investigate whether nebulised hypertonic saline (HS) treatment would decrease length of hospital stay (LOS) among infants with moderate-to severe-bronchiolitis compared with standard supportive care (SC).
We conducted an open, multicentre, randomised clinical trial from 1 April 2013 to 31 March 2016, in Swiss children's hospitals. Patients aged 6 weeks to 24 months with a primary diagnosis of moderate or severe bronchiolitis were included. Children with previous episodes of wheezing, cardiac disease, chronic respiratory disease, immunodeficiency, prematurity (gestational age <34 weeks), corticotherapy in the preceding 2 weeks or inhaled bronchodilators within 24 hours before presentation were excluded. Patients were randomised to receive standard SC with nebulisation of 4 mL of 3% sodium chloride every 6 hours versus SSC. Main outcomes and measures were LOS duration of oxygen therapy, transfer to intensive care unit (ICU), readmission within 7 days following discharge and adverse events.
121 children were randomised. No statistically significant differences were found between treatment groups at baseline (age, Wang Score, atopic history, smoking exposure). Children in the HS group had a non-significant difference in length of stay -2.8 hours (-10; 16) compared with the SC group. There were no differences in oxygen therapy duration, transfer to ICU, readmission rate or adverse events. The intervention was discontinued at the parents' request in 16% of the cases.
Our study does not support the use of HS nebulisation in children with moderate to severe bronchiolitis.
NCT01812525.
Keywords
Administration, Inhalation, Anti-Inflammatory Agents/administration & dosage, Bronchiolitis/drug therapy, Critical Care/statistics & numerical data, Female, Humans, Infant, Length of Stay/statistics & numerical data, Male, Nebulizers and Vaporizers, Oxygen Inhalation Therapy, Prospective Studies, Saline Solution, Hypertonic/administration & dosage, Treatment Outcome, bronchiolitis, length of hospital stay, nebulisation hypertonic saline, randomised controlled trial
Pubmed
Web of science
Open Access
Yes
Create date
17/09/2019 17:19
Last modification date
13/08/2020 5:21
Usage data